TED-N is under clinical development by S.Biomedics and currently in Phase II for Paralysis. According to GlobalData, Phase II drugs for Paralysis have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TED-N’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TED-N overview

Stem cell therapy is under development for the treatment of sub-acute spinal cord injury and paralysis. It is administered through intrathecal route. It comprises of polysialic acid-neural cell adhesion molecule (PSA-NCAM)-positive neural precursor cells (NPC (PSA-NCAM positive)) derived from human embryonic stem cells.

S.Biomedics overview

S.Biomedics specialized in the field of stem cell therapy. It is headquartered in Seongdong, Seoul, South Korea.

For a complete picture of TED-N’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.